Yin Mon Myat
YOU?
Author Swipe
View article: Incidence of second primary malignancies in patients with hematologic malignancies treated with next-generation bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials
Incidence of second primary malignancies in patients with hematologic malignancies treated with next-generation bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials Open
Background: Second primary malignancies (SPMs) have emerged as a clinically relevant concern in patients with hematologic malignancies receiving prolonged targeted therapy. Although next-generation Bruton tyrosine kinase inhibitors (BTKis)…
View article: Advances and challenges in immunotherapy in head and neck cancer
Advances and challenges in immunotherapy in head and neck cancer Open
Head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy with suboptimal survival outcomes despite advances in surgery, radiotherapy, and chemotherapy. Immunotherapy, particularly immune checkpoint inhibitors (ICIs) t…
View article: Trastuzumab deruxtecan: expanding the role of HER2-targeted therapy in solid tumors
Trastuzumab deruxtecan: expanding the role of HER2-targeted therapy in solid tumors Open
View article: A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab
A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab Open
Background: Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow, constituting approximately 13% of all hematologic malignancies. Isatuximab is a monoclona…
View article: Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions
Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions Open
The ever-expanding development of tissue-agnostic therapies which target malignancies based on specific mutations rather than tissue origin have transformed the landscape of oncology. The purpose of this review is to explore the impact, sa…
View article: Histology Agnostic Drug Development: An Updated Review
Histology Agnostic Drug Development: An Updated Review Open
Recent advancements in oncology have led to the development of histology-agnostic therapies, which target genetic alterations irrespective of the tumor’s tissue of origin. This review aimed to provide a comprehensive update on the current …
View article: Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development
Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development Open
The regulatory approvals of tumor-agnostic therapies have led to the re-evaluation of the drug development process. The conventional models of drug development are histology-based. On the other hand, the tumor-agnostic drug development of …
View article: Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug Development
Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug Development Open
The regulatory approvals of tumor agnostic therapies have led to reevaluation of the drug development process. Conventional models of drug development are histology-based. On the other hand, tumor agnostic drug development of a new drug (o…
View article: P1646: A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LYMPHOMA RECEIVING CHEMOTHERAPY
P1646: A SYSTEMATIC REVIEW AND META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LYMPHOMA RECEIVING CHEMOTHERAPY Open
Topic: 34. Thrombosis and vascular biology - Biology & Translational Research Background: Venous thromboembolism (VTE) is a frequent complication of cancer and cancer treatment. Lymphoma is a highly thrombogenic cancer according to the Kho…
View article: Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy
Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy Open
Advanced gastric cancer is a highly thrombogenic cancer per Khorana score. Recent clinical practice guidelines suggest primary outpatient thromboprophylaxis (POTP) for patients with a Khorana score ≥2. We performed an updated meta-analysis…
View article: Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs) Open
View article: Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors
Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors Open